Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 07, 2016 8:37 AM ET


Company Overview of PanOptica, Inc.

Company Overview

PanOptica, Inc., a biopharmaceutical company, licenses and develops a portfolio of therapeutics for ophthalmic diseases. It offers PAN-90806, a small-molecule selective vascular endothelial growth factor receptor antagonist that provides treatment for wet age-related macular degeneration and diabetic retinopathy. The company was founded in 2009 and is based in Bernardsville, New Jersey.

150 Morristown Road

Suite 205

Bernardsville, NJ 07924-2626

United States

Founded in 2009



Key Executives for PanOptica, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 57
Co-founder, Chief Medical Officer and Executive Vice-President
Executive Director of Finance and Controller
Senior Director of Clinical Development
Executive Director of Clinical Operations
Compensation as of Fiscal Year 2015.

PanOptica, Inc. Key Developments

PanOptica Provides Update on its Phase 1 Clinical Trial for PAN-90806

PanOptica announced that it has dosed the first patient in its Phase 1 clinical trial for PAN-90806 less than one month after the company received FDA clearance for its investigational new drug application. The Phase 1 trial is a two-month, open-label study in approximately 30 patients at 15 to 20 clinical sites around the United States. The trial is designed to assess the safety and tolerability of topical ocular PAN-90806 at three dosage strengths in patients with active, subfoveal choroidal neovascularization associated with neovascular AMD. PanOptica expects data readout by the end of 2014. Anti-VEGF therapy is the standard of care for neovascular AMD, but existing treatments require regular physician-administered injections into the eye. An eye-drop formulation has the potential to lower the risk of injection-related complications and significantly reduce the burden on patients, their families and ophthalmology practices.

Similar Private Companies By Industry

Company Name Region
International Frutarom Corp. United States
Kremers Urban Pharmaceuticals Inc. United States
Cerexa, Inc. United States
Oxis Biotech, Inc. United States
Braeburn Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PanOptica, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at